GILD - Why Is Gilead Sciences Stock Trading Higher On Thursday? | Benzinga
Thursday, Gilead Sciences Inc (NASDAQ:GILD) shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial indicating its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.
PURPOSE 1 study met its key efficacy endpoints of the superiority of twice-yearly lenacapavir to once-daily oral Truvada (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV).
Based on these results, the independent Data Monitoring ...